Paracellular calcium transport across Caco-2 and HT29 cell monolayers.
Intestinal calcium absorption has been shown to include two processes, a saturable transcellular movement and a non-saturable paracellular pathway. The potential utility of cell monolayers for studying transepithelial intestinal calcium transport has already been demonstrated; however, simultaneous evaluation of the contribution of the saturable transcellular and of the non-saturable paracellular processes to the total transepithelial transport has not yet been attempted. The aim of this study was to investigate the contribution both of transcellular and paracellular transport processes to the total transepithelial calcium transport in two cell culture monolayers. Caco-2 cells and a clone derived from HT-29 cells (HT29-Cl.19A), two cell lines derived from colon adenocarcinomas which are known to be able to exhibit typical enterocytic differentiation, were used. Cell monolayers were grown on a permeable support and used after 15 days of culture when these cells express enterocytic differentiation and high transepithelial resistance. Isotopic transport rate measurements were performed in the absence of a chemical gradient. The paracellular route was evaluated using [3H]mannitol. Calcium and [3H]mannitol transport rates across cell monolayers were not significantly different. Augmentation of calcium uptake by 200 mM sorbitol did not significantly increase calcium or mannitol transepithelial transport; however, calcium accumulation in the cells was increased by about 200%. Modulation of the monolayer permeability by addition of 10 nM vasoactive intestinal polypeptide (VIP) or 0.5 mM carbachol treatment, which respectively increased and decreased the transepithelial resistance, consequently modified calcium and mannitol transport in a parallel manner. Our results show that Caco-2 and HT29-Cl.19A cell monolayers are good models for studying the calcium paracellular transport pathway.
Blais
A
A
Département de Physiologie, Tour E2, Faculté de Pharmacie Paris XI, 5 rue Jean Baptiste Clément, F-92296 Chatenay-Malabry Cedex, France.
Aymard
P
P
Lacour
B
B
D018938:Caco-2 Cells; D002118:Calcium / Q000378:metabolism*; D002217:Carbachol / Q000494:pharmacology; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D019073:HT29 Cells; D006801:Humans; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D017136:Ion Transport / Q000187:drug effects; D007700:Kinetics; D008353:Mannitol / Q000493:pharmacokinetics; D010042:Ouabain / Q000494:pharmacology; D012964:Sodium / Q000494:pharmacology; D013012:Sorbitol / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
D014660:Vasoactive Intestinal Peptide; D008353:Mannitol; D013012:Sorbitol; D010042:Ouabain; D002217:Carbachol; D012964:Sodium; D002118:Calcium